Bougainville Ventures Inc. (CSE:BOG) (“Bougainville” or the “Company”) is pleased to announce it has closed a private placement (the “Private Placement”) of 1,232,000 units of the Company (each a “Unit”) at a price of $0.25 per Unit, for gross proceeds of $308,000.  The Private Placement was oversubscribed from the previous announcement of up to $150,000 in gross proceeds. The proceeds will be used for general working capital purposes.

Each Unit consists of one common share and one common share purchase warrant exercisable at $0.50  per common share for an exercise term of 12 months ended October 30, 2019. The common shares and common share warrants issued in the placement are subject to a four-month hold period under relevant Canadian securities legislation.


Insiders of the Company purchased a total of 400,000 Units under the Private Placement, which is considered a related party transaction as defined by Multilateral Instrument 61-101 (“MI 61-101”). The Company relied on the exemptions specified in Section 5.5(a) and 5.7(a) of MI 61-101 regarding the related party transaction. No new insiders and no control persons were created in connection with the Private Placement.

The Company has also issued 510,000 common shares at a deemed price of $0.25 as securities for debt owed to certain consultants of the Company.

About Bougainville Ventures, Inc.
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost.

For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors

BOUGAINVILLE VENTURES INC.

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at andy@bougainville.com or 1-844-734-8420

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

Click here to connect with Bougainville Ventures Inc. (CSE:BOG) for an Investor Presentation.

Source: www.stockwatch.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less